Swiss Nordic Bio 2026: LoopLab is developing fusion proteins that are Fc-engagers with the goal of inducing precise, antigen-specific immune tolerance
Founder, Interim CEO & CSO Jochen Stritzker walks us through the platform. The company plans on using it for allergy and autoimmune indications.
Coverage brought to you by










.png)